A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-05-03
Adverse events
Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2023-07-20 (study day 70); relationship: not assessed
Grade 3 Alanine aminotransferase increased — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 105); relationship: not assessed
Grade 2 Fatigue — outcome: RECOVERED/RESOLVED; onset 2023-09-22 (study day 134); relationship: not assessed
Grade 2 Constipation — outcome: RECOVERED/RESOLVED; onset 2023-11-17 (study day 190); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 212); relationship: Y
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-30 (study day 233); relationship: not assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2024-04-04 (study day 329); relationship: N
Data queries
No data queries.